Amide compounds and medicinal use thereof
The present invention relates to a compound of the formula wherein R 1 is substituted aryl, heteroaryl and the like, R 2 and R 3 are hydrogen, alkyl, halogen, hydroxyl group and the like, Q is N, CH and the like, W is hydrogen, alkyl, hydroxycarbonylalkyl and the like, X is halogen, cyano, nitro, amino and the like, X′ is hydrogen, halogen, cyano, nitro, and Y is alkyl, hydroxyl group, alkoxy, mercapto and the like and a salt thereof, and a medicine containing the said compound. The compound of the present invention shows a superior inhibitory effect on activated lymphocytes proliferation and is useful as an agent for the prophylaxis or treatment of various autoimmune diseases.
1. An amide compound of the formula
wherein
R 1 is substituted aryl,
R 2 and R 3 are the same or different and each is hydrogen or alkyl,
Q is nitrogen atom,
W is hydrogen or alkyl,
X is cyano,
X′ is hydrogen, and
Y is optionally substituted piperidino,
or a pharmaceutically acceptable salt thereof.
2. The amide compound of claim 1 , which has the formula
wherein
R 1 is substituted aryl,
R 2 and R 3 are the same or different and each is hydrogen or alkyl,
Q is nitrogen atom,
W is hydrogen or alkyl,
X is cyano,
Y is optionally substituted piperidino,
or a pharmaceutically acceptable salt thereof.
3. An amide compound selected from the group consisting of
N-(3-cyano-4-piperidinophenyl)-1-(4-fluorophenyl)-5-methylpyrazole-4-carboxamide,
N-[3-cyano-4-(4-hydroxypiperidino)phenyl]-1-(4-fluorophenyl)-5-methylpyrazole-4-carboxamide,
1-(4-chlorophenyl)-N-(3-cyano-4-piperidinophenyl)-5-methylpyrazole-4-carboxamide,
1-(4-chlorophenyl)-N-[3-cyano-4-(4-hydroxypiperidin-1-yl)phenyl]-5-methylpyrazole-4-carboxamide,
1-(4-chlorophenyl)-N-[3-cyano-4-(4-morpholinopiperidin-1-yl)phenyl]-5-methylpyrazole-4-carboxamide,
N-(4-{4-[bis(2-hydroxyethyl)amino]piperidin-1-yl}-3-cyanophenyl)-1-(4-chlorophenyl)-5-methylpyrazole-4-carboxamide,
1-(3,4-dichlorophenyl)-N-[3-cyano-4-(4-morpholinopiperidin-1-yl)phenyl]-5-methylpyrazole-4-carboxamide,
N-[3-cyano-4-(4-morpholinopiperidin-1-yl)phenyl]-1-(3,4-difluorophenyl)-5-methylpyrazole-4-carboxamide,
1-(3-chloro-4-fluorophenyl)-N-[3-cyano-4-(4-morpholinopiperidin-1-yl)phenyl]-5-methylpyrazole-4-carboxamide,
N-[3-cyano-4-(4-morpholinopiperidin-1-yl)phenyl]-1-(4-trifluoromethylphenyl)-5-methylpyrazole-4-carboxamide,
N-{4-[4-bis(2-methoxyethyl)aminopiperidin-1-yl]-3-cyanophenyl}-1-(4-chlorophenyl)-5-methylpyrazole-4-carboxamide,
1-(4-chlorophenyl)-N-{3-cyano-4-[4-(2-hydroxyethyl)piperidin-1-yl]phenyl}-5-methylpyrazole-4-carboxamide,
1-(4-bromophenyl)-N-[3-cyano-4-(4-morpholinopiperidino)phenyl]-5-methylpyrazole-4-carboxamide,
N-[3-cyano-4-(4-morpholinopiperidino)phenyl]-1-(4-fluorophenyl)-5-methylpyrazole-4-carboxamide,
N-[3-cyano-4-(4-morpholinopiperidin-1-yl)phenyl]-1-(4-methylphenyl)-5-methylpyrazole-4-carboxamide,
N-[3-cyano-4-(4-morpholinopiperidin-1-yl)phenyl]-1-(4-iodophenyl)-5-methylpyrazole-4-carboxamide,
N-[3-cyano-4-(4-morpholinopiperidin-1-yl)phenyl]-1-(4-methoxyphenyl)-5-methylpyrazole-4-carboxamide,
1-(4-chlorophenyl)-N-[3-cyano-4-(4-thiomorpholinopiperidin-1-yl)phenyl]-5-methylpyrazole-4-carboxamide,
1-(4-chlorophenyl)-N-[3-cyano-4-(4-methoxymethoxypiperidin-1-yl)phenyl]-5-methylpyrazole-4-carboxamide,
1-(4-chlorophenyl)-N-[3-cyano-4-[4-(2-methoxyethoxy)piperidin-1-yl]phenyl]-5-methylpyrazole-4-carboxamide,
N-{3-cyano-4-[4-(2-hydroxyethyl)piperidin-1-yl]phenyl}-1 (4-fluorophenyl)-5-methylpyrazole-4-carboxamide,
N-[3-cyano-(4-morpholinopiperidin-1-yl)phenyl]-5-methyl-1-(4-nitrophenyl)pyrazole-4-carboxamide,
1-(3-chlorophenyl)-N-[3-cyano-4-(4-morpholinopiperidino)phenyl]-5-methylpyrazole-4-carboxamide,
N-[3-cyano-4-(4-morpholinopiperidin-1-yl)phenyl]-1-(3,4-methylenedioxyphenyl)-5-methylpyrazole-4-carboxamide, and
N-[3-cyano-4-(4-morpholinopiperidin-1-yl)phenyl]-1-(3,4-dimethoxyphenyl)-5-methylpyrazole-4-carboxamide,
or a pharmaceutically acceptable salt thereof.
4. A pharmaceutical composition comprising the amide compound of claim 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
5. A method for the treatment of rheumatoid arthritis in a subject, which comprises administering an effective amount of the pharmaceutical composition of claim 4 to the subject.
6. A combination composition comprising an amide compound of the formula
wherein
R 1 is substituted aryl,
R 2 and R 3 are the same or different and each is hydrogen or alkyl,
Q is nitrogen atom,
W is hydrogen or alkyl,
X is cyano,
X′ is hydrogen, and
Y is optionally substituted piperidino,
or a pharmaceutically acceptable salt thereof, and one or more pharmaceutical agents selected from an antirheumatic drug, an immunosuppressive agent, a steroidal drug and a nonsteroidal anti-inflammatory drug.
7. The combination composition of claim 6 , wherein the antirheumatic drug is selected from a gold compound, penicillamine, bucillamine, lobenzarit, actarit and salazosulfapyridine.
8. The combination composition of claim 6 , wherein the immunosuppressive agent is selected from azathioprine, cyclophosphamide, methotrexate, brequinar sodium, deoxyspergualin, mizoribine, 2-morpholinoethyl mycophenolate, cyclosporin, rapamycin, tacrolimus hydrate, leflunomide, OKT-3, anti TNF-α antibody, anti IL-6 antibody and FTY720.
9. The combination composition of claim 6 , wherein the steroidal drug is selected from prednisolone, methylprednisolone, dexamethasone and hydrocortisone.
10. The combination composition of claim 6 , wherein the nonsteroidal anti-inflammatory drug is selected from aspirin, indomethacin, indomethacin farnesil, diclofenac sodium, alclofenac, amfenac sodium, ibuprofen, ketoprofen, loxoprofen sodium, naproxen, pranoprofen, zaltoprofen, mefenamic acid, flufenamic acid, tolufenamic acid, phenylbutazone, ketophenylbutazone, piroxicam, tenoxicam and ampiroxicam.
11. A method for the treatment of atopic dermatitis in a subject, which comprises administering an effective amount of the pharmaceutical composition of claim 4 to the subject.
12. An amide compound selected from the group consisting of
1-(4-chlorophenyl)-N-[3-cyano-4-(4-morpholinopiperidin-1-yl)phenyl]-5-methylpyrazole-4-carboxamide,
1-(4-chlorophenyl)-N-[3-cyano-4-(4-hydroxypiperidin-1-yl)phenyl]-5-methylpyrazole-4-carboxamide,
N-[3-cyano-4-(4-morpholinopiperidin-1-yl)phenyl]-1-(3,4-difluorophenyl)-5-methylpyrazole-4-carboxamide, and
N-[3-cyano-4-(4-morpholinopiperidino)phenyl]-1-(4-fluorophenyl)-5-methylpyrazole-4-carboxamide.
13. A method for the treatment of cerebral meningitis in a subject, which comprises administering an effective amount of the pharmaceutical composition of claim 4 to the subject.
14. A method for the treatment of multiple sclerosis in a subject, which comprises administering an effective amount of the pharmaceutical composition of claim 4 to the subject.
15. A method for the treatment of systemic lupus erythematodes in a subject, which comprises administering an effective amount of the pharmaceutical composition of claim 4 to the subject.
16. A method for the treatment of lupus nephritis in a subject, which comprises administering an effective amount of the pharmaceutical composition of claim 4 to the subject.
17. A method for the treatment of inflammatory bowel disease in a subject, which comprises administering an effective amount of the pharmaceutical composition of claim 4 to the subject.
18. A method for the treatment of psoriasis in a subject, which comprises administering an effective amount of the pharmaceutical composition of claim 4 to the subject.